Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3355 |
|
| Actual shortage: | 217 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-ACYCLOVIR | 400MG | TABLET | Resolved | 2017-03-10 | 2018-01-31 | 18 |
| APO-ACYCLOVIR | 400MG | TABLET | Resolved | 2018-03-05 | 2018-05-24 | 41838 |
| APO-ACYCLOVIR | 400MG | TABLET | Resolved | 2021-06-25 | 2021-07-26 | 141515 |
| APO-ACYCLOVIR | 400MG | TABLET | Resolved | 2020-06-17 | 2020-07-28 | 118040 |
| APO-ACYCLOVIR | 400MG | TABLET | Resolved | 2021-09-17 | 2021-09-27 | 145818 |
| APO-ACYCLOVIR | 400MG | TABLET | Resolved | 2019-07-17 | 2019-08-30 | 89570 |
| APO-ACYCLOVIR | 800MG | TABLET | Resolved | 2017-03-10 | 2017-04-21 | 21 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Resolved | 2020-07-23 | 2020-09-01 | 120964 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Resolved | 2020-01-08 | 2020-02-19 | 102523 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Actual shortage | 2024-12-19 | 2025-05-01 | 246067 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Actual shortage | 2025-03-13 | 2025-05-01 | 252560 |
| APO-ACYCLOVIR OINTMENT | 5% | OINTMENT | Resolved | 2021-11-26 | 2021-12-23 | 150052 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2022-07-11 | 2022-08-11 | 164370 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2018-08-27 | 2018-11-26 | 59284 |
| APO-ALENDRONATE | 5MG | TABLET | Resolved | 2017-10-11 | 2018-03-27 | 25204 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2021-11-22 | 2021-12-01 | 149699 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2019-06-12 | 2019-07-12 | 86271 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2017-03-11 | 2017-06-05 | 633 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2018-05-15 | 2018-07-03 | 49415 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2022-06-06 | 2022-08-11 | 162080 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO PEN VK | Discontinued | 2019-03-08 | 2019-03-08 | 78144 | ||
| APO PEN VK | Discontinued | 2019-03-08 | 2019-03-08 | 78141 | ||
| APO PREDNISONE TAB 1MG USP | 1MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1056 |
| APO PREDNISONE TAB 5MG | 5MG | TABLET | Discontinued | 2018-09-08 | 2018-12-28 | 60699 |
| APO TRIAZIDE | 50MG 25MG | TABLET | Discontinued | 2018-09-08 | 2019-02-13 | 60837 |
| APO-ABACAVIR-LAMIVUDINE-ZIDOVUDINE | 300MG 150MG 300MG | TABLET | Discontinued | 2022-12-12 | 2022-12-12 | 177953 |
| APO-ACEBUTOLOL | 400MG | TABLET | Discontinued | 2017-03-31 | 2018-02-05 | 4965 |
| APO-ACETAMINOPHEN CAPLETS EXTRA STRENGTH | 500MG | TABLET | Discontinued | 2018-09-07 | 2018-09-08 | 60157 |
| APO-ALENDRONATE | 10MG | TABLET | To be discontinued | 2019-01-03 | 2019-12-20 | 71026 |
| APO-ALENDRONATE | 5MG | TABLET | Discontinued | 2019-01-03 | 2019-12-21 | 71023 |
| APO-ALENDRONATE | 10MG | TABLET | To be discontinued | 2018-09-07 | 2019-12-20 | 60163 |
| APO-ALMOTRIPTAN | Discontinued | 2019-05-13 | 2019-05-13 | 83971 | ||
| APO-ALMOTRIPTAN | Discontinued | 2019-05-13 | 2019-05-13 | 83976 | ||
| APO-AMITRIPTYLINE | 50MG | TABLET | To be discontinued | 2025-01-10 | 2025-01-27 | 247469 |
| APO-AMITRIPTYLINE | 50MG | TABLET | To be discontinued | 2019-01-04 | 2021-06-05 | 71354 |
| APO-AMITRIPTYLINE | 10MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71348 |
| APO-AMITRIPTYLINE | 75MG | TABLET | To be discontinued | 2025-01-10 | 2025-01-10 | 247472 |
| APO-AMITRIPTYLINE | 25MG | TABLET | Discontinued | 2025-01-10 | 2025-01-11 | 247466 |
| APO-AMITRIPTYLINE | 25MG | TABLET | Discontinued | 2019-01-04 | 2019-02-13 | 71351 |
| APO-AMITRIPTYLINE | 10MG | TABLET | Discontinued | 2025-01-10 | 2025-01-11 | 247462 |